Company will Lead Educational Sessions and Share
Scientific Advances in Integrated Containment and
Drug Delivery
VIENNA, Nov. 6, 2017 /PRNewswire/ -- (Booth
X67) – West Pharmaceutical Services, Inc. (NYSE: WST), a
global leader in innovative solutions for injectable drug
administration, today announced it will, for the first time,
showcase new extensions of its marketed SmartDose® drug delivery
platform, including several new wearable injectors that allow for
up to 10 mL of volume to be injected in easy-to-use, wearable
formats. In addition, West will lead several educational sessions
and presentations at the PDA Universe of Pre-filled Syringes and
Injection Devices, taking place November
7-8, 2017 in Vienna,
Austria, to address the pharmaceutical industry's top
concerns regarding the containment and delivery of injectable
medicines.
"Advancements in drug development need to be paired with
advances in drug delivery, such as last year's FDA approval of the
first combination product using our SmartDose drug delivery
platform. Based on this technology, we are now excited to
share our expanded portfolio of SmartDose wearable injectors," said
Eric Resnick, Vice President and
Chief Technology Officer at West. "As our customers continue to
innovate and bring to market exciting new therapies to address
important unmet medical needs, West is ready to help them with
advancements in drug containment and delivery and technical
expertise to guide them through the drug development and approval
process."
West's SmartDose drug delivery platform allows patients to
self-administer medication in accordance with their prescribed
treatment. West developed this wearable device with extensive human
factors testing and analysis to understand the interaction between
the patient and the delivery system. All versions of the SmartDose
platform adhere to the patient's body, usually on the abdomen, so
patients can be hands free during administration. The SmartDose
platform offers a variety of integrated solutions for delivery and
containment featuring a silicone-free Daikyo Crystal Zenith®
cartridge and a FluroTec® coated piston containment system. West
has built upon the success of the Generation I (Gen. I) device to
address market needs for higher-dose volumes and enhanced
functionality and usability and now offers for development:
- SmartDose Gen. II device, a system that can accommodate
injection volumes of up to 10 mL, as well as both glass and Daikyo
Crystal Zenith containers.
- SmartDose Gen. III device, a preloaded version, that
reduces user steps and simplifies supply chain.
Both versions will be featured at the conference.
West will participate in the following educational sessions at
the PDA Universe of Pre-filled Syringes and Injection Devices:
- Pre-conference workshops
-
- November 6, 3:00 p.m. – "Why Make Your Existing
Auto-injector 'Smart': Comparison and Benefits of Different
Accessory Form Factors and Integration into a Connected Health
Platform," Brian Lynch, Senior
Director, Innovation at West
- November 6, 3:15 p.m. – "West's SmartDose Platform: A
Wearable Engineered with Both Patient & Pharma Partner in
Mind," Nico Brandes, Director,
Market Development, I&T at West
- November 6, 3:30 p.m. – "Particulates in Sterile Drug
Products: Testing and Contributions from Packaging Components,"
Fran DeGrazio, Vice President of
Scientific Affairs & Technical Services at West
- Scientific program sessions
-
- November 7, 2:25 p.m. – "Advances in Intradermal Drug
Delivery: From Vaccines to Immunotherapy and Beyond," Yotam Levin, Chief Executive Officer at
NanoPassTM Technologies Ltd., a strategic partner of
West
- November 7, 4:55 p.m. – "The Changing Diabetes Landscape:
Linking Diagnostics with Injection," Aileen
Kinsella, Director of Segment Marketing at West
- November 8, 7:30 a.m. – "PDA Interest Group Meeting:
Packaging Science," moderated by Bettine
Boltres, Manager, Technical Customer Services at West, and
Derek Duncan, Vice President of
Marketing at Lighthouse Instruments
- November 8, 9:00 a.m. – "Clinical Needs: Patient-Device
Interface," moderated by Mike
Schaefers, Vice President and General Manager, Global Pharma
at West
- Post-conference workshops
Christa Jansen-Otten, Director, Global Product
Management, Prefilled Systems & Delivery at West, will lead two
sessions in the workshop, "Development and Manufacturing of
Pre-filled Syringes: A Hands-on Training":
-
- November 9, 9:05 a.m. – "Advantages of Pre-filled Syringe
and Market Trends in Primary Packaging"
- November 10, 11:00 a.m. – "Elastomeric Closures for
Pre-filled Syringes and Cartridges"
Tibor
Hlobik, Sr. Director, Global Product Management, Prefilled
Systems & Delivery at West, will lead a session on "Drug
Delivery Systems: Global Technical, Regulatory and Quality
Challenges": November 9,
3:30 p.m.
Additionally, West will present three scientific posters, which
will be available in the Exhibit Hall during the conference:
- "Determination of Piston Movement in Low Pressure/High Altitude
Conditions in Daikyo Crystal Zenith Containers," Rohit Vora, Engineer, Container Systems, R&D
at West
- "PFS Plunger Evaluations in Different Auto-injection Modes,"
Fran DeGrazio, Vice President of
Scientific Affairs & Technical Services at West
- "Risk-Based Approach to Achieving 'Zero-Defect' Products
for Personalized Medicine Applications," John Dinka, Senior
Director, Pharmaceutical Processing, R&D at West
For more information on West products and services, please visit
booth X67 at PDA Universe of Pre-filled Syringes and Injection
Devices or visit us online at www.westpharma.com.
Forward-Looking Statements
Certain forward-looking
statements are included in this release. These statements reflect
management's current expectations regarding future events and
operating performance and speak only as of the date of this
release. There is no certainty that West's SmartDose® drug delivery
platform, or any other products, will achieve any level of
commercial success. These forward-looking statements involve a
number of risks and uncertainties. For a description of certain
additional factors that could cause West's future results to differ
from those expressed in any such forward-looking statements, see
Item 1A, entitled "Risk Factors," in West's Annual Report on Form
10-K for the year ended December 31,
2016. Except as required by law or regulation, we undertake
no obligation to publicly update any forward-looking statements,
whether as a result of new information, future events, or
otherwise.
About West
West Pharmaceutical Services, Inc. is a
leading manufacturer of packaging components and delivery systems
for injectable drugs and healthcare products. Working by the side
of its customers from concept to patient, West creates products
that promote the efficiency, reliability and safety of the world's
pharmaceutical drug supply. West is headquartered in Exton, Pennsylvania, and supports its
customers from locations in North and South America, Europe, Asia
and Australia. West's 2016 net
sales of $1.5 billion reflect the
daily use of approximately 112 million of its components and
devices, which are designed to improve the delivery of healthcare
to patients around the world.
West and the diamond logo and FluroTec are trademarks or
registered trademarks of West Pharmaceutical Services, Inc., in
the United States and other
jurisdictions.
SmartDose® is a registered trademark of
Medimop Medical Projects Ltd., a subsidiary of West Pharmaceutical
Services, Inc.
Daikyo Crystal Zenith® is a registered
trademark of Daikyo Seiko, Ltd. Daikyo Crystal Zenith and FluroTec
technologies are licensed from Daikyo Seiko,
Ltd.
NanoPass is a trademark of NanoPass
Technologies Ltd.
Media Contact:
Emily
Denney
Global Communications
West Pharmaceutical Services, Inc.
+ 1-610-594-3035
Emily.Denney@westpharma.com
Logo -
http://mma.prnewswire.com/media/597034/West_tagline_1_blue_RGB.jpg